title: Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A.
abstract: Matrix metalloproteinase-2 (MMP-2) is known to degrade type IV collagen,             which is a major component of the cellular basement membrane, and to be involved             in the invasion and metastasis of cancer cells. On the other hand, C-reactive             protein (CRP) and serum amyloid A (SAA) are acute inflammatory biomarkers that             increase in various conditions including infection, inflammation, malignancy and             tissue disturbance. In the present study, we examined the serum levels of MMP-2,             CRP and SAA in patients with localized and metastatic non-small cell lung cancer             (NSCLC) to establish the clinical significance and changes in these biomarkers             during NSCLC progression. In this study, 24 NSCLC patients were diagnosed at the             Kitasato University Hospital and compared with 13 healthy controls. Measurement             of MMP-2 levels in serum was determined by measuring pro-MMP-2 using a one-step             sandwich enzyme immunoassay. CRP and SAA levels in the serum were measured by             latex nephelometry. The serum levels of MMP-2, CRP and SAA in metastatic NSCLC             patients were significantly higher than in localized NSCLC patients (p<0.01).             There was a significant positive correlation between serum MMP-2 and CRP levels             as well as SAA levels in metastatic NSCLC patients (p<0.01). Therefore, quantitation             of MMP-2, CRP and SAA in NSCLC patients may be an auxiliary indicator to monitor             tumor progression and poor prognosis of NSCLC disease.
authors.affiliation: Department of Laboratory Medicine, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan. kanoh@med.kitasato-u.ac.jp
authors.forename: Yuhsaku
authors.initials: Y
authors.lastname: Kanoh
authors.forename: Tadashi
authors.initials: T
authors.lastname: Abe
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
authors.forename: Tohru
authors.initials: T
authors.lastname: Akahoshi
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000175:diagnosis / Q000556:secondary; D016022:Case-Control Studies; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D000685:Serum Amyloid A Protein / Q000378:metabolism*; D018709:Statistics, Nonparametric
chemical_list: D014408:Biomarkers, Tumor; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein; D020778:Matrix Metalloproteinase 2